Last reviewed 2026-04-20 · How we verify

Panitumumbab

Roswell Park Cancer Institute · Phase 1 active Biologic Quality 0/100

Panitumumbab is a Biologic drug developed by Roswell Park Cancer Institute. It is currently in Phase 1 development. Also known as: ABX-EGF, ABX-EGF Monoclonal Antibody.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Panitumumbab
Also known as	ABX-EGF, ABX-EGF Monoclonal Antibody
Sponsor	Roswell Park Cancer Institute
Modality	Biologic
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Panitumumbab CI brief — competitive landscape report
Panitumumbab updates RSS · CI watch RSS
Roswell Park Cancer Institute portfolio CI

Frequently asked questions about Panitumumbab

What is Panitumumbab?

Panitumumbab is a Biologic drug developed by Roswell Park Cancer Institute.

Who makes Panitumumbab?

Panitumumbab is developed by Roswell Park Cancer Institute (see full Roswell Park Cancer Institute pipeline at /company/roswell-park-cancer-institute).

Is Panitumumbab also known as anything else?

Panitumumbab is also known as ABX-EGF, ABX-EGF Monoclonal Antibody.

What development phase is Panitumumbab in?

Panitumumbab is in Phase 1.

Manufacturer: Roswell Park Cancer Institute — full pipeline
Therapeutic area: All drugs in Other
Also known as: ABX-EGF, ABX-EGF Monoclonal Antibody

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing